Ali Sharma, Ph.D.

2002-2004 Nathan Kline Institute, New York University Medical School, Orangeburg, NY, United States 
 2004-2011 Neuroscience Albert Einstein College of Medicine of Yeshiva University, NY, United States 
 2011-2016 Pharmacology Weill Cornell Medical College, New York, NY, United States 
 2016-2019 Icahn School of Medicine at Mount Sinai, New York, NY, United States 
 2019- National Institutes of Health, Bethesda 
Fragile X Syndrom, Alzhiemer's Disease, mTOR, DNA methylation, neurodegenerative diseases
"Ali Sharma"

Dr. Ali Sharma is a graduate of the State University of New York at Purchase, where he received a B.S. in Biology. He holds a Ph.D. in neuroscience from the Albert Einstein College of Medicine in New York and received his postdoctoral training in the Department of Pharmacology at Weill Cornell Medicine.

Before joining CSR, Dr. Sharma was at the National Institute on Aging as Health Specialist, where he was involved with Alzheimer’s translational research. Prior to this appointment, he was an assistant professor of pharmacological sciences at Icahn School of Medicine at Mount Sinai, where his research was focused on characterization and validation of molecular subtypes and key molecular network drivers in Alzheimer's disease (AD) using electrophysiology approaches in AD transgenic mice. He also initiated and managed an electrophysiology core facility at Mount Sinai.

Mean distance: 16.25 (cluster 16)


Sign in to add mentor
R. Suzanne Zukin grad student 2004-2011 Albert Einstein College of Medicine of Yeshiva University
 (PIKE as critical regulator of mTOR signaling and synaptic dysfunction in Fragile X syndrome.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Mariottini C, Munari L, Gunzel E, et al. (2019) Wilm's tumor 1 promotes memory flexibility. Nature Communications. 10: 3756
Frolinger T, Herman F, Sharma A, et al. (2018) Epigenetic modifications by polyphenolic compounds alter gene expression in the hippocampus. Biology Open
Wang J, Hodes GE, Zhang H, et al. (2018) Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice. Nature Communications. 9: 477
Choi CH, Schoenfeld BP, Bell AJ, et al. (2016) Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models. Frontiers in Behavioral Neuroscience. 10: 136
Zupan B, Sharma A, Frazier A, et al. (2016) Programming social behavior by the maternal fragile X protein. Genes, Brain, and Behavior
Mitchell E, Klein SL, Argyropoulos KV, et al. (2016) Behavioural traits propagate across generations via segregated iterative-somatic and gametic epigenetic mechanisms. Nature Communications. 7: 11492
Sharma A, Klein SS, Barboza L, et al. (2016) Principles Governing DNA Methylation during Neuronal Lineage and Subtype Specification. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 1711-22
Sharma A, Hoeffer CA, Takayasu Y, et al. (2010) Dysregulation of mTOR signaling in fragile X syndrome. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 694-702
Petanceska SS, DeRosa S, Sharma A, et al. (2003) Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. Journal of Molecular Neuroscience : Mn. 20: 395-406
Petanceska SS, DeRosa S, Olm V, et al. (2002) Statin therapy for Alzheimer's disease: will it work? Journal of Molecular Neuroscience : Mn. 19: 155-61
See more...